Coagulant Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 17

Coagulant Therapeutics General Information

Description

Developer of hemostatic medicines designed to treat acute bleeding, an unmet medical need. The company's drugs offer an optimized, proprietary rFVIIa molecule, termed CT-001, for the prevention and treatment of acute bleeding and other coagulation cascade-related diseases and leverages expertise in biologics to develop novel therapeutics targeted to treat adjacencies, enabling doctors to treat traumatic injury and save the lives of many young people.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2630 Bancroft Way
  • Berkeley, CA 94704
  • United States
+1 (855)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2630 Bancroft Way
  • Berkeley, CA 94704
  • United States
+1 (855)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Coagulant Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private Completed Pre-Clinical Trials
4. Early Stage VC (Series A2) 22-Apr-2021 Completed Pre-Clinical Trials
3. Early Stage VC 21-Jan-2020 Completed Startup
2. Early Stage VC (Series A1) 08-Jul-2019 $21M $21M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Coagulant Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Coagulant Therapeutics Patents

Coagulant Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023229091-A1 Camelid antibodies against activated protein c and uses thereof Pending 04-Mar-2022
EP-4486381-A2 Camelid antibodies against activated protein c and uses thereof Pending 04-Mar-2022
EP-4486381-A4 Camelid antibodies against activated protein c and uses thereof Pending 04-Mar-2022
WO-2023168429-A2 Camelid antibodies against activated protein c and uses thereof Inactive 04-Mar-2022
WO-2023168429-A3 Camelid antibodies against activated protein c and uses thereof Inactive 04-Mar-2022 C07K16/40
To view Coagulant Therapeutics’s complete patent history, request access »

Coagulant Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Coagulant Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aventures Capital Management Venture Capital Minority
Colopl Next Corporate Venture Capital Minority
DT & Investment Corporate Venture Capital Minority
G.N. Tech Venture Capital Venture Capital Minority
Hana Financial Group Holding Company Minority
You’re viewing 5 of 17 investors. Get the full list »

Coagulant Therapeutics FAQs

  • When was Coagulant Therapeutics founded?

    Coagulant Therapeutics was founded in 2019.

  • Where is Coagulant Therapeutics headquartered?

    Coagulant Therapeutics is headquartered in Berkeley, CA.

  • What is the size of Coagulant Therapeutics?

    Coagulant Therapeutics has 4 total employees.

  • What industry is Coagulant Therapeutics in?

    Coagulant Therapeutics’s primary industry is Drug Discovery.

  • Is Coagulant Therapeutics a private or public company?

    Coagulant Therapeutics is a Private company.

  • What is Coagulant Therapeutics’s current revenue?

    The current revenue for Coagulant Therapeutics is .

  • How much funding has Coagulant Therapeutics raised over time?

    Coagulant Therapeutics has raised $38M.

  • Who are Coagulant Therapeutics’s investors?

    Aventures Capital Management, Colopl Next, DT & Investment, G.N. Tech Venture Capital, and Hana Financial Group are 5 of 17 investors who have invested in Coagulant Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process